NCT03188536

Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study)

Clinical and Sociodemographic Characterization of Multiple Myeloma Patients With Symptomatic Relapse and/or Refractory Disease in Spain

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 282 (actual)
• Sponsor: Takeda · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to characterize the multiple myeloma (MM) participants with symptomatic relapse and/or refractory disease in Spain.

Detailed description

Adult participants with a diagnosis of MM who have received at least one previous treatment line and have experienced symptomatic relapse and/or refractory disease in the previous 6 months, who are still in follow-up at the time of the study visit will be observed in this study. The study will look into sociodemographic data, current clinical and therapeutic data, clinical data relative to the latest relapse and clinical data at diagnosis and previous relapses will be collected. The study will enroll approximately 350 patients. This multi-center trial will be conducted in a total of 30 public sites in Spain. The overall time to collect data will be approximately 1 year from June 2017 to May 2018.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
OTHER	No Intervention	As it was an observational study, no intervention was administered in this study.

Timeline

• Start date: 2017-07-26
• Primary completion: 2018-11-15
• Completion: 2019-01-30
• First posted: 2017-06-15
• Last updated: 2020-10-12
• Results posted: 2020-10-12

Locations

30 sites across 1 country: Spain